CLDN18 and gastric cancer: Our study revealed that GC with CLDN18-ARHGAP fusion could also activate PI3K-AKT-mTOR-FAS to enhance FFA production and promote Treg cells proliferation and survival in the TME by means of bioinformatic analysis, in vitro and in vivo experiments.